# Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development
## Abbreviations
_Atherosclerosis_**2004**, _176_, 255-263. [CrossRef]
* [PERSON] et al. (1986) [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. _Proc. Natl. Acad. Sci. USA_**1986**, _83_, 8370-8374. [CrossRef]
* [PERSON] et al. (1986) [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON] [PERSON]; et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. _Biochim. Biophys. Acta (BBA)/Lipids Lipid Metab._**1986**, _877_, 50-60. [CrossRef]
* [PERSON] (1999) [PERSON]; [PERSON] [PERSON] Effect of cervastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHLR rabbits. _Br. J. Pharmacol._**1999**, _126_, 961-968. [CrossRef]
* [PERSON] et al. (2003) [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON] Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHLL) rabbits. _J. Atheroscler. Thromb._**2003**, _10_, 109-116. [CrossRef]* [PERSON] et al. (1998) [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON] Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. _Circulation_**1998**, _98_, 2088-2093. [CrossRef]
* [PERSON] and [PERSON] (1998) [PERSON]; [PERSON]. Lack of predictability of classical animal models for hypolipidemic activity: A good time for mice? _Atherosclerosis_**1998**, _140_, 15-24. [CrossRef]
* [PERSON] and [PERSON] (1998) [PERSON]; [PERSON] [PERSON] Regulation of apo A-I gene expression by fibrates. _Atherosclerosis_**1998**, _137_, S19-S23. [CrossRef]
* [PERSON] et al. (1995) [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON] Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I. Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits. _Folia Pharmacol. Jpn._**1995**, _106_, 41-50. [CrossRef] [PubMed]
* [PERSON] et al. (2007) [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON] Fenofibrate induces plaque regression in hypercholesterolic atherosclerotic rabbits: In vivo demonstration by high-resolution MRI. _Atherosclerosis_**2007**, _190_, 106-113. [CrossRef] [PubMed]
* [PERSON] et al. (2009) [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON]; [PERSON] Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits. _Cardiowasc. Pathol._**2009**, _18_, 140-147. [CrossRef] [PubMed]
* [PERSON] et al. (2016) [PERSON]; [PERSON]; [PERSON]; [PERSON] [PERSON] The role of ezetimibe in the treatment of cardiovascular disease. _Curr. Atheroscler. Rep._**2016**, _18_, 8. [CrossRef]
* [PERSON] (2009) [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON] Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. _Br. J. Pharmacol._**2009**, _156_, 1218-1227. [CrossRef]
* [PERSON] et al. (2011) [PERSON]; [PERSON] [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON] [PERSON]; [PERSON]; [PERSON]; [PERSON] Plaque rupture and thrombosis are reduced by lowering cholesterol levels and crystallization with ezetimibe and are correlated with fluorodeoxyglucose positron emission tomography. _Arterioscler. Thromb. Vasc. Biol._**2011**, _31_, 2007-2014. [CrossRef]
* [PERSON] et al.